HALOZYME THERAPEUTICS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
HALOZYME THERAPEUTICS, INC. (HALO) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $65.80 million as of 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2021-08-09
- 2021-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $65.80M.
- 2021-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $80.60M.
- 2020-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $21.20M.
- 2020-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $27.40M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2021-06-30 | $65.80M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $80.60M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $21.20M 10-K · filed 2021-02-23 |
| 2020-09-30 | $27.40M 10-Q · filed 2020-11-02 |
| 2020-03-31 | $129.90M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $82.90M 10-K · filed 2020-02-24 |
| 2019-06-30 | $23.00M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $71.20M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $167.30M 10-K · filed 2019-02-21 |
| 2017-12-31 | $183.60M 10-K · filed 2018-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |